CD274 and neoplasm: We need to further investigate whether the findings of the present study can be confirmed in the tumor-bearing mouse model, especially whether the regulated signal pathways by the three multi-RTK inhibitors are affected by the new first-line immune checkpoint inhibitors such as anti-PD-L1 inhibitor durvalumab, anti-PD1 monoclonal antibody pembrolizumab or anti–CTLA-4 antibody tremelimumab.